Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARKLE: Systemic Treatment with MDT in Oligorecurrent Prostate Cancer
NCT05352178Phase 3Recruiting
- Sponsor
- UZ Leuven
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enzalutamide, goserelin, leuprorelin extended-release injection and triptorelin in prostate cancer (PCa), sponsored by UZ Leuven. Primary endpoint: Poly-metastatic free survival at 5 years. Started Apr 2022; status: recruiting.
02
Drugs
enzalutamidegoserelinleuprorelin extended-release injectiontriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05352178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352178.